Aventis/Novartis update
This article was originally published in The Tan Sheet
Executive Summary
No formal negotiations have taken place on price tag for France's number one pharmaceutical company, Aventis CEO Igor Landau says in an April 2 conference call. Landau said the firm has "close to two months" to accelerate price negotiations if Novartis maintains interest; Aventis will propose resolutions including a 2003 dividend to shareholders at a May 19 annual meeting. If the merger is successful, Novartis likely would spin off non-core pharmaceutical and consumer brands into a separate entity (1"The Tan Sheet" March 29, 2004, p. 5)...
You may also be interested in...
Novartis/Aventis Consumer Products Combo Would Be Divested
Novartis would spin-off a combination of its consumer health products and Aventis' older drugs if the two companies were to merge
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.